Selzentry

Selzentry is a brand name of maraviroc, approved by the FDA in the following formulation(s):

SELZENTRY (maraviroc - tablet; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: August 6, 2007
  
  Strength(s): 150MG, 300MG ^[RLD]

Has a generic version of Selzentry been approved?

No. There is currently no therapeutically equivalent version of Selzentry available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Selzentry. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  CCR5 modulators
  Patent 6,586,430
  Issued: July 1, 2003
  Inventor(s): Duncan Robert; Armour & David Anthony; Price & Blanda Luzia Christa; Stammen & Anthony; Wood & Manoussos; Perros & Martin Paul; Edwards
  Assignee(s): Pfizer Inc.
  Compounds of Formula 1 [Region &agr;]-[Region &bgr;]-[Region &ggr;]-[Region &dgr;]  (I) which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and methods of treatment using these compounds.
  
  Patent expiration dates:
  
  
  • December 1, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Tropane derivatives useful in therapy
  Patent 6,667,314
  Issued: December 23, 2003
  Inventor(s): Manoussos; Perros & David Anthony; Price & Blanda Luzia Christa; Stammen & Anthony; Wood
  Assignee(s): Pfizer, Inc.
  The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
  
  Patent expiration dates:
  
  
  • August 6, 2021
    
    ✓ 
    Patent use: METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Tropane derivatives useful in therapy
  Patent 7,368,460
  Issued: May 6, 2008
  Inventor(s): Perros; Manoussos & Price; David Anthony & Stammen; Blanda Luzia Christa & Wood; Anthony
  Assignee(s): Pfizer, Inc.
  The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
  
  Patent expiration dates:
  
  
  • November 25, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
  
  



• 
  Tropane derivatives useful in therapy
  Patent 7,576,097
  Issued: August 18, 2009
  Inventor(s): Perros; Manoussos & Price; David Anthony & Stammen; Blanda Luzia Christa & Wood; Anthony
  Assignee(s): Pfizer, Inc.
  The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
  
  Patent expiration dates:
  
  
  • May 25, 2021
    
    ✓ 
    Drug substance
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 6, 2012 - NEW CHEMICAL ENTITY
  
  
  • May 28, 2013 - NEW PATIENT POPULATION
  
  

See also...

• Selzentry Consumer Information (Drugs.com)
• Selzentry Consumer Information (Wolters Kluwer)
• Selzentry Consumer Information (Cerner Multum)
• Selzentry Advanced Consumer Information (Micromedex)
• Selzentry AHFS DI Monographs (ASHP)
• Maraviroc Consumer Information (Wolters Kluwer)
• Maraviroc Consumer Information (Cerner Multum)
• Maraviroc Advanced Consumer Information (Micromedex)
• Maraviroc AHFS DI Monographs (ASHP)